SYRE Valuation

Spyre Therapeutics Inc

Add to Watchlist

Advanced Chart

14.660

-0.570(-3.740%)

Overview
Forecast
Valuation

SYRE Relative Valuation

SYRE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SYRE is overvalued; if below, it's undervalued.

Historical Valuation

Spyre Therapeutics Inc (SYRE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of 164.59. The fair price of Spyre Therapeutics Inc (SYRE) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 14.66 USD , Spyre Therapeutics Inc is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：14.66

Fair

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

2.54

P/B

Median3y

-94.45

Median5y

-55.38

-17.39

FCF Yield

Median3y

-155.96

Median5y

-102.96

Competitors Valuation Multiple

The average P/S ratio for SYRE's competitors is 21342.79, providing a benchmark for relative valuation. Spyre Therapeutics Inc Corp (SYRE) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SYRE.O

Spyre Therapeutics Inc

Loss

Average P/S: 21342.79

883.64M